Literature DB >> 29574790

The role of enhancer of zeste homolog 2: From viral epigenetics to the carcinogenesis of hepatocellular carcinoma.

Luca Sanna1, Irene Marchesi1, Mariarosa A B Melone2,3, Luigi Bagella1,3.   

Abstract

Nowadays, epigenetics covers a crucial role in different fields of science. The enhancer of zeste homolog 2 (EZH2), the catalytic subunit of the Polycomb Repressive Complex 2 (PRC2), is a big proponent of how epigenetic changes can affect the initiation and progression of several diseases. Through its catalytic activity, responsible for the tri-methylation of lysine 27 of the histone H3 (H3K27me3), EZH2 is a good target for both diagnosis and therapy of different pathologies. A large number of studies have demonstrated its crucial role in cancer initiation and progression. Nevertheless, only recently its function in virus diseases has been uncovered; therefore, EZH2 can be an important promoter of viral carcinogenesis. This review explores the role of EZH2 in viral epigenetics based on recent progress that demonstrated the role of this protein in virus environment. In particular, the review focuses on EZH2 behavior in Hepatitis B Virus, analyzing its role in the rise of Hepatocellular Carcinoma.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  EZH2; HBV; HCC; epigenetics; virus

Mesh:

Substances:

Year:  2018        PMID: 29574790     DOI: 10.1002/jcp.26545

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  9 in total

Review 1.  Berberine, a Herbal Metabolite in the Metabolic Syndrome: The Risk Factors, Course, and Consequences of the Disease.

Authors:  Anna Och; Marek Och; Renata Nowak; Dominika Podgórska; Rafał Podgórski
Journal:  Molecules       Date:  2022-02-17       Impact factor: 4.411

Review 2.  Biotechnology-based microbial degradation of plastic additives.

Authors:  Rob T Lumio; Mario A Tan; Hilbert D Magpantay
Journal:  3 Biotech       Date:  2021-06-21       Impact factor: 2.893

3.  Sex-biased genetic programs in liver metabolism and liver fibrosis are controlled by EZH1 and EZH2.

Authors:  Dana Lau-Corona; Woo Kyun Bae; Lothar Hennighausen; David J Waxman
Journal:  PLoS Genet       Date:  2020-05-19       Impact factor: 5.917

4.  Identification of a Necroptosis-Related Prognostic Signature and Associated Regulatory Axis in Liver Hepatocellular Carcinoma.

Authors:  Aoxiao He; Zhihao Huang; Jiakun Wang; Hongcheng Lu; Rongguiyi Zhang; Linquan Wu; Qian Feng
Journal:  Dis Markers       Date:  2022-07-09       Impact factor: 3.464

5.  Liver-specific deletion of miR-181ab1 reduces liver tumour progression via upregulation of CBX7.

Authors:  Jinbiao Chen; Yang Zhao; Fan Zhang; Jia Li; Jade A Boland; Ngan Ching Cheng; Ken Liu; Jessamy C Tiffen; Patrick Bertolino; David G Bowen; Andreas Krueger; Leszek Lisowski; Ian E Alexander; Mathew A Vadas; Emad El-Omar; Jennifer R Gamble; Geoffrey W McCaughan
Journal:  Cell Mol Life Sci       Date:  2022-07-22       Impact factor: 9.207

6.  Exosomal miR-101-3p and miR-423-5p inhibit medulloblastoma tumorigenesis through targeting FOXP4 and EZH2.

Authors:  Ping Xue; Saihua Huang; Xiao Han; Caiyan Zhang; Lan Yang; Wenfeng Xiao; Jinrong Fu; Hao Li; Yufeng Zhou
Journal:  Cell Death Differ       Date:  2021-07-22       Impact factor: 15.828

Review 7.  A Natural Isoquinoline Alkaloid With Antitumor Activity: Studies of the Biological Activities of Berberine.

Authors:  Da Liu; Xue Meng; Donglu Wu; Zhidong Qiu; Haoming Luo
Journal:  Front Pharmacol       Date:  2019-02-14       Impact factor: 5.810

Review 8.  Biological Activity of Berberine-A Summary Update.

Authors:  Anna Och; Rafał Podgórski; Renata Nowak
Journal:  Toxins (Basel)       Date:  2020-11-12       Impact factor: 4.546

9.  Comprehensive Pan-Cancer Genomic Analysis Reveals PHF19 as a Carcinogenic Indicator Related to Immune Infiltration and Prognosis of Hepatocellular Carcinoma.

Authors:  Zheng-Yi Zhu; Ning Tang; Ming-Fu Wang; Jing-Chao Zhou; Jing-Lin Wang; Hao-Zhen Ren; Xiao-Lei Shi
Journal:  Front Immunol       Date:  2022-01-05       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.